TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results
01 mars 2022 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, March 01, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2021, and recent company...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
25 févr. 2022 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis...
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update
24 févr. 2022 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Tuesday, March 1, 2022 at 8:30 AM ET to discuss results for...
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
15 févr. 2022 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials...
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
24 janv. 2022 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in a...
TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present at the 40th...
TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million
04 janv. 2022 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been...
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting
14 déc. 2021 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two data presentations, highlighted data from the UNITY-CLL Phase 3 trial evaluating the combination...
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
14 déc. 2021 07h15 HE
|
TG Therapeutics, Inc.
Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022 NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug...
TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting
13 déc. 2021 07h30 HE
|
TG Therapeutics, Inc.
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced four data presentations, including three oral presentations and one poster presentation, evaluating...